C12Y 310/01001
N-sulfoglucosamine sulfohydrolase
Official title: N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
C12Y310/01001 (N-sulfoglucosamine sulfohydrolase) appears on 31 US grants and 67 published applications in this corpus.
Search patents in C12Y- Granted patents
- 31
- Published applications
- 67
- Assignees
- 23
- Inventors
- 116
- Latest grant
- 9 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 5 |
| 2014 | 0 | 1 |
| 2015 | 2 | 1 |
| 2016 | 2 | 6 |
| 2017 | 2 | 3 |
| 2018 | 2 | 8 |
| 2019 | 1 | 2 |
| 2020 | 4 | 8 |
| 2021 | 2 | 2 |
| 2022 | 4 | 5 |
| 2023 | 3 | 7 |
| 2024 | 5 | 2 |
| 2025 | 4 | 11 |
| 2026 | 0 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- CNS delivery of therapeutic agents9 Sep 2025US 12,409,210 B2Takeda Pharmaceutical Company Limited
- Methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders10 Jun 2025US 12,324,829 B2Nationwide Children's Hospital, Inc.
- Plant lectins as carriers of associated drug substances into animal and human cells15 Apr 2025US 12,275,968 B2Biostrategies Lc
- Sulfamidase (SGSH) variants, vectors, compositions and methods and uses for treating mucopolysaccharidosis type IIIA (MPS IIIA)11 Feb 2025US 12,221,635 B2The Childeren's Hospital of Philadelphia
- Methods and compositions for CNS delivery of arylsulfatase A17 Dec 2024US 12,168,041 B2Takeda Pharmaceutical Company Limited
- Methods of increasing sialic acid levels in recombinant glycosylated proteins8 Oct 2026US 2026/0308601 A1Denali Therapeutics Inc.
- Peptide Having Affinity for Human Transferrin Receptor24 Sep 2026US 2026/0285942 A1JCR Pharmaceuticals Co., Ltd.
- AAV-SGSH Vectors for Treatment of Mucopolysaccharidosis IIIA3 Sep 2026US 2026/0256944 A1The University of North Carolina at Chapel Hill
- Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier2 Jul 2026US 2026/0184781 A1JCR Pharmaceuticals Co., Ltd.
- Novel process for purifying heparan-n-sulfatase2 Apr 2026US 2026/0092264 A1The Green Cross Corporation
Most cited
By later US patents
- Methods and compositions for CNS delivery of heparan N-sulfatase18US 9,320,711 B2Shire Human Genetic Therapies, Inc. · 2016
- Methods and compositions for CNS delivery of iduronate-2-sulfatase13US 9,220,677 B2Shire Human Genetic Therapies, Inc. · 2015
- Fusion proteins comprising enzyme replacement therapy enzymes11US 10,870,837 B2Denali Therapeutics Inc. · 2020
- CNS delivery of therapeutic agents6US 10,456,454 B2Shire Human Genetic Therapies, Inc. · 2019
- Treatment of Sanfilippo syndrome type B by intrathecal administration of alpha-n-acetylglucosaminidase6US 9,814,764 B2Shire Human Genetic Therapies, Inc. · 2017